The Pathophysiology of Cardiac Hypertrophy and Heart Failure

William E. Stansfield, Mark Ranek, Avani Pendse, Jonathan C. Schisler, Shaobin Wang, Thomas Pulinilkunnil, Monte Willis

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

Left ventricular hypertrophy (LVH) is one of the most common cardiovascular diseases; the estimated prevalence is 20% in the general population. In spite of being one of the greatest independent risk factors for cardiovascular morbidity and mortality, it remains essentially untreated. In this chapter, we review the complex interplay of physiologic systems that give rise to pathologic hypertrophy and heart failure. We explore the hierarchy of intra- and intercellular signaling systems that converge to produce the hypertrophic phenotype. Lastly, we consider novel access points within these systems that may represent new therapeutic windows for pharmacologic intervention.

Original languageEnglish (US)
Title of host publicationCellular and Molecular Pathobiology of Cardiovascular Disease
PublisherElsevier Inc.
Pages51-78
Number of pages28
ISBN (Print)9780124052062
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Cardiomegaly
Left Ventricular Hypertrophy
Hypertrophy
Cardiovascular Diseases
Heart Failure
Morbidity
Phenotype
Mortality
Population
Therapeutics

Keywords

  • Calcineurin
  • Congestive heart failure (CHF)
  • FAK
  • GPCR
  • HDAC
  • Hypertrophy
  • Left ventricular hypertrophy (LVH)
  • MAPK
  • MicroRNA
  • Mitochondria
  • MTOR
  • NFAT
  • NO
  • Pathologic hypertrophy
  • Proteasome
  • Reactive oxygen species (ROS)
  • SRF
  • TNF
  • Ubiquitin

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Stansfield, W. E., Ranek, M., Pendse, A., Schisler, J. C., Wang, S., Pulinilkunnil, T., & Willis, M. (2014). The Pathophysiology of Cardiac Hypertrophy and Heart Failure. In Cellular and Molecular Pathobiology of Cardiovascular Disease (pp. 51-78). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-405206-2.00004-1

The Pathophysiology of Cardiac Hypertrophy and Heart Failure. / Stansfield, William E.; Ranek, Mark; Pendse, Avani; Schisler, Jonathan C.; Wang, Shaobin; Pulinilkunnil, Thomas; Willis, Monte.

Cellular and Molecular Pathobiology of Cardiovascular Disease. Elsevier Inc., 2014. p. 51-78.

Research output: Chapter in Book/Report/Conference proceedingChapter

Stansfield, WE, Ranek, M, Pendse, A, Schisler, JC, Wang, S, Pulinilkunnil, T & Willis, M 2014, The Pathophysiology of Cardiac Hypertrophy and Heart Failure. in Cellular and Molecular Pathobiology of Cardiovascular Disease. Elsevier Inc., pp. 51-78. https://doi.org/10.1016/B978-0-12-405206-2.00004-1
Stansfield WE, Ranek M, Pendse A, Schisler JC, Wang S, Pulinilkunnil T et al. The Pathophysiology of Cardiac Hypertrophy and Heart Failure. In Cellular and Molecular Pathobiology of Cardiovascular Disease. Elsevier Inc. 2014. p. 51-78 https://doi.org/10.1016/B978-0-12-405206-2.00004-1
Stansfield, William E. ; Ranek, Mark ; Pendse, Avani ; Schisler, Jonathan C. ; Wang, Shaobin ; Pulinilkunnil, Thomas ; Willis, Monte. / The Pathophysiology of Cardiac Hypertrophy and Heart Failure. Cellular and Molecular Pathobiology of Cardiovascular Disease. Elsevier Inc., 2014. pp. 51-78
@inbook{3da9472f75794269afd167ad5853928c,
title = "The Pathophysiology of Cardiac Hypertrophy and Heart Failure",
abstract = "Left ventricular hypertrophy (LVH) is one of the most common cardiovascular diseases; the estimated prevalence is 20{\%} in the general population. In spite of being one of the greatest independent risk factors for cardiovascular morbidity and mortality, it remains essentially untreated. In this chapter, we review the complex interplay of physiologic systems that give rise to pathologic hypertrophy and heart failure. We explore the hierarchy of intra- and intercellular signaling systems that converge to produce the hypertrophic phenotype. Lastly, we consider novel access points within these systems that may represent new therapeutic windows for pharmacologic intervention.",
keywords = "Calcineurin, Congestive heart failure (CHF), FAK, GPCR, HDAC, Hypertrophy, Left ventricular hypertrophy (LVH), MAPK, MicroRNA, Mitochondria, MTOR, NFAT, NO, Pathologic hypertrophy, Proteasome, Reactive oxygen species (ROS), SRF, TNF, Ubiquitin",
author = "Stansfield, {William E.} and Mark Ranek and Avani Pendse and Schisler, {Jonathan C.} and Shaobin Wang and Thomas Pulinilkunnil and Monte Willis",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-405206-2.00004-1",
language = "English (US)",
isbn = "9780124052062",
pages = "51--78",
booktitle = "Cellular and Molecular Pathobiology of Cardiovascular Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - The Pathophysiology of Cardiac Hypertrophy and Heart Failure

AU - Stansfield, William E.

AU - Ranek, Mark

AU - Pendse, Avani

AU - Schisler, Jonathan C.

AU - Wang, Shaobin

AU - Pulinilkunnil, Thomas

AU - Willis, Monte

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Left ventricular hypertrophy (LVH) is one of the most common cardiovascular diseases; the estimated prevalence is 20% in the general population. In spite of being one of the greatest independent risk factors for cardiovascular morbidity and mortality, it remains essentially untreated. In this chapter, we review the complex interplay of physiologic systems that give rise to pathologic hypertrophy and heart failure. We explore the hierarchy of intra- and intercellular signaling systems that converge to produce the hypertrophic phenotype. Lastly, we consider novel access points within these systems that may represent new therapeutic windows for pharmacologic intervention.

AB - Left ventricular hypertrophy (LVH) is one of the most common cardiovascular diseases; the estimated prevalence is 20% in the general population. In spite of being one of the greatest independent risk factors for cardiovascular morbidity and mortality, it remains essentially untreated. In this chapter, we review the complex interplay of physiologic systems that give rise to pathologic hypertrophy and heart failure. We explore the hierarchy of intra- and intercellular signaling systems that converge to produce the hypertrophic phenotype. Lastly, we consider novel access points within these systems that may represent new therapeutic windows for pharmacologic intervention.

KW - Calcineurin

KW - Congestive heart failure (CHF)

KW - FAK

KW - GPCR

KW - HDAC

KW - Hypertrophy

KW - Left ventricular hypertrophy (LVH)

KW - MAPK

KW - MicroRNA

KW - Mitochondria

KW - MTOR

KW - NFAT

KW - NO

KW - Pathologic hypertrophy

KW - Proteasome

KW - Reactive oxygen species (ROS)

KW - SRF

KW - TNF

KW - Ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=84902749129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902749129&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-405206-2.00004-1

DO - 10.1016/B978-0-12-405206-2.00004-1

M3 - Chapter

SN - 9780124052062

SP - 51

EP - 78

BT - Cellular and Molecular Pathobiology of Cardiovascular Disease

PB - Elsevier Inc.

ER -